drugset / Trial / NCT07096934

Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care

NCT07096934 ↗

Phase 1/2 Not yet recruiting 120 enrolled FibroBiologics
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, multicentre, randomized clinical trial evaluating the safety, tolerability, and efficacy of up to 12 weeks treatment with SoC + low- or high-dose CYWC628 in treating DFU, compared to SoC only.

Timeline

Start
2025-09
Primary completion
2026-03
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CYWC628 Unknown — —

Indications